BRAF and colorectal cancer: Uric acid, one of the top five parameters with the highest SHAP values in our model, has been reported in the literature to be associated with colorectal cancer development, BRAF mutation, and shorter progression-free survival (PFS) in non-metastatic colorectal cancer patients receiving doublet chemotherapy [19,20,21,22].